Katie Gordon
Geen lopende functies
Profiel
Prior to joining Harvard's Office of Technology Development in 2004, Dr. Gorgon served as a consultant to several early-stage biomedical companies in the areas of strategic development and operations/management.
She previously founded and ran biotechnology company Apollo BioPharmaceutics, a neuroscience company that developed novel neuroprotective compounds for Alzheimer's disease and ophthalmic indications and was by acquired by MitoKor Corp.
Prior to Apollo/MitoKor, she was a Director at Genzyme Corporation.
Dr. Gordon was a post-doctoral fellow at Yale University and holds a PhD from Wesleyan University.
Eerdere bekende functies van Katie Gordon
| Bedrijven | Functie | Einde |
|---|---|---|
Office of Technology Development
 Office of Technology Development Investment ManagersFinance Office of Technology Development (Office of Technology Development) is a venture capital subsidiary of Harvard University founded in 2007. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 30-06-2009 |
| LINEAGE CELL THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-04-2006 |
Opleiding van Katie Gordon
| Wesleyan University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| LINEAGE CELL THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Office of Technology Development
Office of Technology Development Investment ManagersFinance Office of Technology Development (Office of Technology Development) is a venture capital subsidiary of Harvard University founded in 2007. The firm is headquartered in Cambridge, Massachusetts. | Finance |
